DexCom DXCM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 239.4%-4.9pp | 237.3%-10.4pp | 237.7%-12.8pp | 240.3%-12.3pp | 244.3%-9.5pp | |
| Operating margin | 74.2%+10.9pp | 68%+2.8pp | 63.3%-3.5pp | 62%-3.8pp | 63.3%+0.8pp | |
| Net margin | 66.5%+5.1pp | 60.1%-5.2pp | 56.4%-9.5pp | 57.7%-2.1pp | 61.4%+7.3pp | |
| EBITDA margin | 95.9%+11.1pp | 89.7%+3.4pp | 85.1%-2.7pp | 83.7%-2.7pp | 84.7%+1.9pp | |
| Free cash flow margin | 89.6%+29.6pp | 73.8%+12.3pp | 66.3%+6.4pp | 56.3%-4.8pp | 59.9%+1.2pp | |
| Returns | ||||||
| Return on equity | 123.6%+10.8pp | 111.7%-6.0pp | 104.8%-11.0pp | 106.2%+4.1pp | 112.8%+23.7pp | |
| Return on assets | 45.4%+8.0pp | 39.6%-0.4pp | 35.6%-4.6pp | 35.7%-0.6pp | 37.4%+5.0pp | |
| Return on invested capital | 162.1%+27.1pp | 146.6%+10.4pp | 137.4%+3.8pp | 125.5%+5.5pp | 135%+32.6pp | |
| Efficiency | ||||||
| Asset turnover | 2.7×+0.3× | 2.6×+0.2× | 2.5×+0.1× | 2.5×+0.1× | 2.4×+0.1× | |
| Inventory turnover | 12.4×+0.8× | 12.4×+0.8× | 12.1×+0.3× | 11.8×-0.3× | 11.6×-0.5× | |
| Liquidity | ||||||
| Current ratio | 6.9×-1.3× | 6.5×-3.2× | 6.1×-5.0× | 6.9×-4.4× | 8.2×-2.7× | |
| Quick ratio | 6×-1.3× | 5.6×-2.8× | 5.3×-4.3× | 6.1×-3.9× | 7.2×-2.5× | |
| Cash ratio | 1.8×+0.4× | 1.6×0.0× | 1.4×-0.4× | 1.2×-0.6× | 1.4×-0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -4.2×-1.3× | -4.3×-1.5× | -4.2×-1.5× | -3.1×-0.2× | -2.9×+0.8× | |
| Per Share | ||||||
| Book value per share | $27.28+27.9% | $25.33+19.8% | $23.65+13.1% | $21.78+1.8% | $21.32+4.3% | |
| Valuation | ||||||
| Market capitalization | $110.78B-14.2% | $113.39B-27.2% | $117.88B-31.8% | $118.36B-35.0% | $129.11B-30.9% | |
| Enterprise value | $106.31B-16.1% | $109.12B-28.9% | $113.92B-33.2% | $115.64B-35.7% | $126.63B-31.3% | |
| Price / earnings | 153.6×-56.2× | 177.7×-65.7× | 199.4×-78.7× | 202.3×-132× | 209.8×-197× | |
| Price / sales | 24.4×-7.8× | 25.8×-14.0× | 27.8×-17.6× | 28.8×-20.5× | 32.2×-21.1× | |
| Price / book | 40.6×-17.7× | 44.3×-26.1× | 49.3×-29.5× | 53.2×-28.0× | 58.4×-28.0× | |
| EV / EBITDA | 99.8×-48.5× | 112.1×-68.0× | 127.1×-76.3× | 134.4×-90.5× | 148.3×-107× | |
| EV / sales | 23.4×-8.2× | 24.9×-14.4× | 26.9×-17.9× | 28.1×-20.5× | 31.6×-21.0× | |
| Free cash flow yield | 15.8%+8.1pp | 12%+5.4pp | 9.9%+4.3pp | 7.9%+2.8pp | 7.7%+3.2pp | |
| Earnings yield | 11.5%+3.6pp | 9.6%+2.5pp | 8.3%+1.9pp | 8.1%+3.2pp | 7.9%+3.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are DexCom's profit margins?
- DexCom (DXCM) runs a 61.5% gross margin and a 21.4% operating margin, with a 19.3% net margin.
- Where do DexCom's ratios come from?
- Every ratio is computed from DexCom's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
